Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Prospective, Single-arm, Phase II Clinical Study of the Efficacy and Safety of Donafenib Plus Sintilimab Combined With Transarterial Chemoembolization (TACE) in Patients With BCLC Stage B/C Hepatocellular Carcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05507632
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:39:01.389918+00:00
Published At
2022-08-19T00:00:00+00:00
Record Updated At
2022-08-19
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Unresectable Hepatocellular Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2022-08-19"
protocolSection.identificationModule.nctId
"NCT05507632"
protocolSection.identificationModule.officialTitle
"A Prospective, Single-arm, Phase II Clinical Study of the Efficacy and Safety of Donafenib Plus Sintilimab Combined With Transarterial Chemoembolization (TACE) in Patients With BCLC Stage B/C Hepatocellular Carcinoma"
protocolSection.statusModule.overallStatus
"NOT_YET_RECRUITING"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Unresectable Hepatocellular Carcinoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.